These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
179 related articles for article (PubMed ID: 1504110)
1. Anxiogenic properties of yohimbine. I. Behavioral, physiological and biochemical measures. Albus M; Zahn TP; Breier A Eur Arch Psychiatry Clin Neurosci; 1992; 241(6):337-44. PubMed ID: 1504110 [TBL] [Abstract][Full Text] [Related]
2. Anxiogenic properties of yohimbine. II. Influence of experimental set and setting. Albus M; Zahn TP; Breier A Eur Arch Psychiatry Clin Neurosci; 1992; 241(6):345-51. PubMed ID: 1504111 [TBL] [Abstract][Full Text] [Related]
3. Psychophysiological and biochemical changes in patients with panic attacks in a defined situational arousal. Braune S; Albus M; Fröhler M; Höhn T; Scheibe G Eur Arch Psychiatry Clin Neurosci; 1994; 244(2):86-92. PubMed ID: 7948059 [TBL] [Abstract][Full Text] [Related]
4. Anxiogenic properties of a computer simulation for panic disorder with agoraphobia. Freire RC; De Carvalho MR; Joffily M; Zin WA; Nardi AE J Affect Disord; 2010 Sep; 125(1-3):301-6. PubMed ID: 20100626 [TBL] [Abstract][Full Text] [Related]
5. Behavioral, sympathetic and adrenocortical responses to yohimbine in panic disorder patients and normal controls. Gurguis GN; Vitton BJ; Uhde TW Psychiatry Res; 1997 Jun; 71(1):27-39. PubMed ID: 9247979 [TBL] [Abstract][Full Text] [Related]
6. Platelet alpha 2-adrenoreceptors, catecholamines, hemodynamic variables, and anxiety in panic patients and their asymptomatic relatives. Cameron OG; Smith CB; Nesse RM; Hill EM; Hollingsworth PJ; Abelson JA; Hariharan M; Curtis GC Psychosom Med; 1996; 58(4):289-301. PubMed ID: 8827791 [TBL] [Abstract][Full Text] [Related]
7. Effects of the serotonin reuptake inhibitor fluvoxamine on yohimbine-induced anxiety in panic disorder. Goddard AW; Woods SW; Sholomskas DE; Goodman WK; Charney DS; Heninger GR Psychiatry Res; 1993 Aug; 48(2):119-33. PubMed ID: 8416022 [TBL] [Abstract][Full Text] [Related]
8. Physiological, biochemical and subjective parameters in anxiety patients with panic disorder during stress exposure as compared with healthy controls. Hoehn T; Braune S; Scheibe G; Albus M Eur Arch Psychiatry Clin Neurosci; 1997; 247(5):264-74. PubMed ID: 9444496 [TBL] [Abstract][Full Text] [Related]
9. Neurobiological mechanisms of panic anxiety: biochemical and behavioral correlates of yohimbine-induced panic attacks. Charney DS; Woods SW; Goodman WK; Heninger GR Am J Psychiatry; 1987 Aug; 144(8):1030-6. PubMed ID: 3037926 [TBL] [Abstract][Full Text] [Related]
10. Noradrenergic neuronal dysregulation in panic disorder: the effects of intravenous yohimbine and clonidine in panic disorder patients. Charney DS; Woods SW; Krystal JH; Nagy LM; Heninger GR Acta Psychiatr Scand; 1992 Oct; 86(4):273-82. PubMed ID: 1333719 [TBL] [Abstract][Full Text] [Related]
11. Noradrenergic function in panic anxiety. Effects of yohimbine in healthy subjects and patients with agoraphobia and panic disorder. Charney DS; Heninger GR; Breier A Arch Gen Psychiatry; 1984 Aug; 41(8):751-63. PubMed ID: 6742977 [TBL] [Abstract][Full Text] [Related]
12. Alprazolam premedication and 35% carbon dioxide vulnerability in panic patients. Pols H; Verburg K; Hauzer R; Meijer J; Griez E Biol Psychiatry; 1996 Nov; 40(9):913-7. PubMed ID: 8896779 [TBL] [Abstract][Full Text] [Related]
13. Pentagastrin infusions in patients with panic disorder. I. Symptoms and cardiovascular responses. Abelson JL; Nesse RM Biol Psychiatry; 1994 Jul; 36(2):73-83. PubMed ID: 7948449 [TBL] [Abstract][Full Text] [Related]
14. Adrenergic status in anxiety disorders: platelet alpha 2-adrenergic receptor binding, blood pressure, pulse, and plasma catecholamines in panic and generalized anxiety disorder patients and in normal subjects. Cameron OG; Smith CB; Lee MA; Hollingsworth PJ; Hill EM; Curtis GC Biol Psychiatry; 1990 Jul; 28(1):3-20. PubMed ID: 2165422 [TBL] [Abstract][Full Text] [Related]
15. Avoidance behaviour: a predictor of the efficacy of pharmacotherapy in panic disorder? Maier W; Roth SM; Argyle N; Buller R; Lavori P; Brandon S; Benkert O Eur Arch Psychiatry Clin Neurosci; 1991; 241(3):151-8. PubMed ID: 1790160 [TBL] [Abstract][Full Text] [Related]
16. Aversive imagery in panic disorder: agoraphobia severity, comorbidity, and defensive physiology. McTeague LM; Lang PJ; Laplante MC; Bradley MM Biol Psychiatry; 2011 Sep; 70(5):415-24. PubMed ID: 21550590 [TBL] [Abstract][Full Text] [Related]